Results 101 to 110 of about 4,697 (156)

Comparative Efficacy of BTK Inhibitors in Treatment-Naïve and Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Review and Meta-Analysis. [PDF]

J Cell Mol Med
Xu F, Zou X, Yang Y, Zhou K, Huang W.
europepmc   +1 more source

Peripheral and central nervous system toxicities of Bruton tyrosine kinase Inhibitors: a real-world pharmacovigilance study. [PDF]

Front Med (Lausanne)
Zhang J.
europepmc   +1 more source

Generational safety profiles of BTK inhibitors: adverse reaction signals and real-world evidence from the FAERS database. [PDF]

Front Med (Lausanne)
Tu J, Wang Z, Zhang J, Xu H, Li Y, Zhang L, Gong J, Zhao L.   +7 more
europepmc   +1 more source

Real-world comparative effectiveness of first-line BTK inhibitors in chronic lymphocytic leukemia. [PDF]

Future Oncol
Hou JZ, Choksi R, Maglinte GA, Wang X, Rui PA, Suryavanshi M, Allendorf D, Patel T, Dadla A, Fontaine A, Jonglertham P, Aton L, Hagan M, Morere L, Scott J, Williams R, Ermann DA.   +16 more
europepmc   +1 more source

BTK Inhibitors for the Treatment of Mantle Cell Lymphoma-Current Status and Perspectives. [PDF]

Cancers (Basel)
Robak T, Wolska-Washer A, Robak P.
europepmc   +1 more source

Acalabrutinib monotherapy as a first-line treatment for CLL: 3-year follow-up of the real-world EPIC study. [PDF]

Blood Adv
Eyre TA, Martinez-Calle N, Paneesha S, Norouzi M, Tucker D, Walter H, Boden A, Kilner M, Phillips N, Patten PEM, Shah N, Ruparelia M, Oddy S, Tsawayo T, Forconi F, Wardle H, Gbemre T, Gregory C, Cook L, Allsup D, Morris A, Knechtli C, Davies J, Galani J, Marr H, Hutchinson C, Williams S, Hickey J, Harding H, Hunjan S, Blak BT, Walewska R.   +31 more
europepmc   +1 more source

Efficacy of high-frequency low-dose rituximab and acalabrutinib in chronic lymphocytic leukemia. [PDF]

Hemasphere
Chu CC, Heffernan CB, Jaimes-Delgadillo NC, Herne CA, Bruno JE, Baran AM, Ashton JM, Mosmann TR, Barr PM, Taylor RP, Elliott MR, Zent CS.   +11 more
europepmc   +1 more source

Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience. [PDF]

Br J Haematol
Duminuco A, Leotta D, Allegra A, Caracciolo D, Caruso L, Chiarenza A, Del Fabro V, Di Martina V, Figuera A, Fiumara PF, Gentile M, Innao V, Mancuso S, Martino EA, Mosca A, Motta G, Pedalino F, Rossi M, Stagno F, Tona G, Di Raimondo F, Palumbo GA.   +21 more
europepmc   +1 more source

From breath to block: Disseminated invasive aspergillosis presenting with pulmonary, ocular, myocardial and cerebral involvement, and high-grade atrioventricular block during acalabrutinib therapy for chronic lymphocytic leukaemia. [PDF]

IDCases
Young AB, Birkby S, Knight D, Leslie S.
europepmc   +1 more source

Continuous or fixed-duration BTK inhibitor treatment for WM. [PDF]

Blood Adv
Yi S, Qiu L.
europepmc   +1 more source